Related Experiment Video
Updated: Jun 11, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Therapy of chronic lymphocytic leukaemia
1Klinik I für Innere Medizin, Center for Integrated Oncology Köln Bonn, Universität zu Köln, Joseph-Stelzmann Str. 9, 50924 Köln, Germany. michael.hallek@uni-koeln.de
Abstract:
Rapid progress has been achieved recently in the management of chronic lymphocytic leukaemia (CLL). New insights into the molecular pathology of CLL have generated a plethora of biological markers that predict the prognosis and influence therapeutic decisions. Moreover, fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab, have been approved by European and/or American regulatory agencies. Additional monoclonal antibodies targeting CD20, CD23, CD37, CD38 or CD40, as well as drugs designed to interfere with proteins regulating the cell cycle, apoptotic machinery or leukaemic microenvironment (e.g., flavopiridol, oblimersen, ABT-263 or lenalidomide) are investigated in clinical trials. An increased experience with reduced-intensity allogeneic progenitor cell transplantation allows offering this option to physically fit patients. This review attempts to summarise the current use of these different modalities in CLL therapy.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiprotozoal Agents
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

